Document Detail

Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
MedLine Citation:
PMID:  11274933     Owner:  NLM     Status:  MEDLINE    
Despite scientific evidence that secondary prevention medical therapies reduce mortality in patients with established coronary artery disease, these therapies continue to be underutilized in patients receiving conventional care. To address this issue, a Cardiac Hospital Atherosclerosis Management Program (CHAMP) focused on initiation of aspirin, cholesterol-lowering medication (hydroxymethylglutaryl coenzyme A [HMG CoA] reductase inhibitor titrated to achieve low-density lipoprotein [LDL] cholesterol < or =100 mg/dl), beta blocker, and angiotensin-converting enzyme (ACE) inhibitor therapy in conjunction with diet and exercise counseling before hospital discharge in patients with established coronary artery disease. Treatment rates and clinical outcome were compared in patients discharged after myocardial infarction in the 2-year period before (1992 to 1993) and the 2-year period after (1994 to 1995) CHAMP was implemented. In the pre- and post-CHAMP patient groups, aspirin use at discharge improved from 68% to 92% (p <0.01), beta blocker use improved from 12% to 62% (p <0.01), ACE inhibitor use increased from 6% to 58% (p <0.01), and statin use increased from 6% to 86% (p <0.01). This increased use of treatment persisted during subsequent follow-up. There was also a significant increase in patients achieving a LDL cholesterol < or =100 mg/dl (6% vs 58%, p <0.001) and a reduction in recurrent myocardial infarction and 1-year mortality. Compared with conventional guidelines and care, CHAMP was associated with a significant increase in use of medications that have been previously demonstrated to reduce mortality; more patients achieved an LDL cholesterol < or =100 mg/dl, and there were improved clinical outcomes in patients after hospitalization for acute myocardial infarction.
G C Fonarow; A Gawlinski; S Moughrabi; J H Tillisch
Related Documents :
20816133 - Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pre...
8750253 - Percentage change rather than plasma level of ldl-cholesterol determines therapeutic re...
8033183 - Radionuclide techniques in the selection of patients for ptca and in post-ptca evaluation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  87     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-03-29     Completed Date:  2002-01-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  819-22     Citation Subset:  AIM; IM    
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, Department of Medicine, Los Angeles, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / administration & dosage,  therapeutic use
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  therapeutic use
Antilipemic Agents / administration & dosage,  therapeutic use
Aspirin / administration & dosage,  therapeutic use
Cholesterol, LDL / blood
Cohort Studies
Coronary Artery Disease / prevention & control*
Disease Management*
Hospitals, University
Los Angeles
Myocardial Infarction / prevention & control*
Patient Compliance*
Patient Education as Topic
Preventive Health Services / standards*
Program Evaluation
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antilipemic Agents; 0/Cholesterol, LDL; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The expanding world of co-stimulation: the two-signal model revisited.
Next Document:  Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after...